Segmental Myoclonus Following Hepatorenal Transplant and Tacrolimus Immunosuppression - 19/12/20
Doi : 10.1016/j.pediatrneurol.2020.09.008
Aaron Michael McLaughlin, MD a, b, ⁎ 
, Tuba Rashid Khan, MD, MPH, EdM a, b, Jonathan Lauritsen, DO c, Kaitlin Batley, MD a, Jeff Lynn Waugh, MD, PhD a, c
, Tuba Rashid Khan, MD, MPH, EdM a, b, Jonathan Lauritsen, DO c, Kaitlin Batley, MD a, Jeff Lynn Waugh, MD, PhD a, c a Division of Child Neurology, Department of Pediatrics, University of Texas Southwestern, Dallas, Texas
b Neurodevelopmental Disabilities Residency Program, University of Texas Southwestern, Dallas, Texas
c Division of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas, Texas
∗Communications should be addressed to: Dr. McLaughlin; Division of Pediatric Neurology; Department of Pediatrics; University of Texas Southwestern Medical Center; 5323, Harry Hines Blvd.; Dallas, TX 75390-9063.Division of Pediatric NeurologyDepartment of PediatricsUniversity of Texas Southwestern Medical Center5323, Harry Hines Blvd.DallasTX75390-9063
Keywords : Myoclonus, Segmental, Hepatorenal transplant, Tacrolimus, Methylmalonic acidemia
| The authors declare no conflict of interest or financial disclosures concerning the materials or methods used in this study or the findings specified in this article. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 114
P. 40-41 - janvier 2021 Retour au numéro
Article précédent
- Treatment of Low Cerebrospinal Fluid 5-Methyltetrahydrofolate With Leucovorin Improves Seizure Control and Development in PCDH19-Related Epilepsy
- Deborah L. Renaud
- Successful Treatment of Pediatric FIRES With Anakinra
- Jennifer H. Yang, Shilpa Nataraj, Shifteh Sattar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?